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leep-wake alternation is an essential component
of human biological rhythms,and physiological processes
accompanying sleep are fundamental to body recovery.As
reflected in waking performance,sleep is one of the major
determinants of brain function.Quality of life,productiv-
ity,health,and effective education all depend on the qual-
ity of normal brain function.However,the economic and
social development in our modern society has led,and will
lead,to chronic disruption of sleep in a sizeable proportion
of the population.The main contributors to these disrup-
tions can be classified as either environmental (noise and
light pollution),economic/societal (shift-work schedule),
or pathological (sleep disorders).The detrimental effects
of these factors on sleep increase with age and are
expected to have an even larger impact in the future,given
the aging population and the increased prevalence/inci-
dence of shift work.
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S
Sleep laboratory investigations constitute a unique noninvasive tool to analyze brain functioning. Polysomnographic
recordings, even in the very early phase of development in humans, are mandatory in a developmental plan of a new
sleep-acting compound. Sleep is also an interesting tool for the development of other drugs acting on the central ner-
vous system (CNS). Indeed, changes in sleep electroencephalographic (EEG) characteristics are a very sensitive indication
of the objective central effects of psychoactive drugs, and these changes are specific to the way the drug acts on the brain
neurotransmitter systems. Moreover, new compounds can be compared with reference drugs in terms of the sleep EEG
profile they induce. For instance, cognitive enhancers involving cholinergic mechanism have been consistently demon-
strated to increase rapid eye movement (REM) sleep pressure, and studying drug-induced slow wave sleep (SWS) alter-
ation is a particularly useful tool for the development of CNS compounds acting at the 5-HT2A/C receptor, such as most
atypical antipsychotics and some antidepressant drugs. The sleep EEG profile of antidepressants, and particularly their
effects on REM sleep, are specific to their ability to enhance noradrenergic or serotonergic transmission. It is suggested
that the effects of noradrenergic versus serotonergic reuptake inhibition could be disentangled using specific monoamine
depletion tests and by studying drug effects on sleep microstructure. Dialogues Clin Neurosci. 2002;4:342-350.
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At the present time,as much as one third of the adult pop-
ulation reports difficulty sleeping,
1-3 and sleep disturbance
is considered as the second most common symptom of
mental distress.
4The widespread use of prescribed hypnotic
medication as well as nonprescription remedies is an indi-
rect reflection of the high frequency of sleep complaints.
2,5
Sleep disorders are often chronic conditions: one study
found that over 40% of those reporting sleep problems
had had them for more than 5 years.
1 Individuals reporting
disturbed sleep are more likely to report emotional distress
and recurrent health problems.
1A major prospective inves-
tigation suggests that these problems are the consequence
and not the cause of sleep difficulties.
6 Deviant sleep pat-
tern has also been identified as a potentially important
problem for physical health.Those who report shorter than
average sleep duration (“short-sleepers”) as well as those
reporting long sleep duration (“long-sleepers”) have been
shown to have an increased risk of mortality.
7-9
Despite recent inroads into understanding of the sleep-reg-
ulatory neural circuit,
10-13 current treatments for sleep dis-
orders act via a limited number of pathways. Most hyp-
notics target GABAergic (GABA,γ-aminobutyric acid)
activity globally in the brain.Other commonly used hyp-
notics that were not designed to treat insomnia (sedative
antidepressants and antihistamines) have long half-lives
and peripheral side effects.Current treatments for hyper-
somnia typically enhance dopaminergic transmission.New
drugs designed for treating restless legs syndrome and peri-
odic limb movement during sleep are needed.In a similar
way,studies are needed to understand why most sedatives
exacerbate disordered breathing during sleep,and to design
countermeasures,or even drugs preventing,sleep apnea.
As recently stressed by Mignot et al,
13 the rapid growth of
basic and clinical sleep research promises to lead to new
and more targeted pharmacotherapy for sleep disorders.
Thus,new drugs for therapeutic application in sleep dis-
order medicine are clearly needed. For this purpose,
objective assessments of drug effects with polysomno-
graphic recordings,even in the very early phase of devel-
opment in humans, are mandatory in a developmental
plan for a new sleep-acting compound. In the present
paper,arguments for using sleep as a tool for the devel-
opment of other drugs acting on the central nervous sys-
tem (CNS) will be presented.In the following sections,
we will discuss how the relationship between sleep phys-
iology and neurotransmitter function could be used for
the development of CNS-acting drugs.
REM sleep pressure as a surrogate marker 
of a cognitive enhancer acting on cholinergic
neurotransmission
The cholinergic system  is one of the most important
modulatory neurotransmitters in the brain and controls
many activities that depend on selective attention and
conscious awareness.Drugs that antagonize muscarinic
receptors induce hallucinations and reduce the level of
consciousness,while the nicotinic receptor is implicated
in the mode of action of general anesthetics.
14 In degen-
erative diseases of the brain,such as Alzheimer’s disease,
dementia with Lewy bodies,or Parkinson’s disease,alter-
ations in consciousness,loss of memory,visual hallucina-
tions,or rapid eye movement (REM) sleep abnormali-
ties have been associated with regional deficits in the
cholinergic system. In the following sections, we will
briefly discuss the value of using REM sleep as a surro-
gate marker of compounds acting on cholinergic neuro-
transmission,and particularly in the development of cog-
nitive enhancers for Alzheimer’s disease.
REM sleep
REM sleep was first described in 1953 by Aserinsky and
Kleitman.
15 At regular 90- to 100-min intervals, they
observed the spontaneous emergence of electroen-
cephalographic (EEG) desynchronization accompanied
by clusters of rapid saccadic eye movements.When sub-
jects were awakened during such an episode,they gen-
erally reported that they had been dreaming.REM sleep
is also called paradoxical sleep because of the close
resemblance to the EEG of active wakefulness combined
Selected abbreviations and acronyms
CNS central nervous system
EEG electroencephalography
GABA γ-aminobutyric acid
GH growth hormone
5-HT 5-hydroxytryptamine (serotonin)
NSRI noradrenaline and serotonin reuptake inhibitor
PET positron emission tomography
REM rapid eye movement
SNRI selective noradrenaline reuptake inhibitor
SSRI selective serotonin reuptake inhibitor
SWS slow wave sleep
TDT tryptophan depletion testwith a “paradoxical” active inhibition of major muscle
groups that seems to reflect deep sleep.Normal sleep is
characterized in EEG terms as recurrent cycles of non-
REM and REM sleep of about 90 min.Non-REM sleep
is subdivided into stages 1 through 4,with stage 1 being
the lightest and stage 4 being the deepest sleep. In the
successive cycles of the night,the amounts of stages 3 and
4 (also known as slow wave sleep [SWS]) decrease,and
the proportion of the cycle occupied by REM sleep tends
to increase, with REM episodes occurring late in the
night having more eye movement bursts than REM
episodes occurring early in the night.
Disturbances in REM sleep organization can be assessed
by measuring its total amount (expressed in minutes or
as a percentage of total sleep time), its onset latency
(REM latency), its distribution across the successive
non-REM/REM cycles during the night,and  the actual
number of rapid eye movements (REM activity) during
this sleep stage or per minute of REM sleep (REM den-
sity). For instance, an increased propensity for REM
sleep (or increased REM sleep pressure) is described as
a greater amount of REM sleep mostly at the beginning
of the night (also reflected by a shortened REM latency)
and an increase in REM activity and REM density.
Acetylcholine, REM sleep, and Alzheimer’s disease
At the present time,there is clear evidence for choliner-
gic mechanisms in the generation of REM sleep,and this
has been the subject of many studies for the last four
decades.
16-18Animal studies have demonstrated that the
expression of REM sleep-related physiology (eg,thala-
mocortical arousal,pontogeniculate-occipital waves,and
atonia) depends upon a subpopulation of brain stem
pediculopontine tegmental neurons that release acetyl-
choline to act upon muscarinic receptors.
19 Since a vari-
able degree of cell loss in the pediculopontine region has
been reported in Alzheimer’s disease, it is tempting to
speculate that the cholinergic deficit induces REM
sleep–specific abnormalities such as decreased REM
duration and density,increased REM latency,and REM
sleep behavior disorder.
14,19
More generally,human studies indicate that acute admin-
istration of muscarinic cholinergic agonists increase
REM sleep propensity,whereas acute administration of
muscarinic antagonists produce the opposite effect.
20
Based upon the pharmacological profile of the com-
pounds used to manipulate sleep,it appears that both M1
and M2 muscarinic receptor subtypes are involved in
REM sleep regulation.
20 Regarding acetylcholinesterase
inhibitors,studies in healthy volunteers have shown that
physostigmine,
21 tacrine,
22 and rivastigmine
23,24 increase
REM sleep pressure. Interestingly, another acetyl-
cholinesterase inhibitor,donepezil,may have a role in the
treatment of REM sleep behavior disorder,
25 a syndrome
characterized by the appearance of elaborate motor
activity associated with dream mentation due to the
intermittent loss of REM sleep muscular atonia.
In summary,the study of REM sleep propensity in nor-
mal subjects is a particularly useful tool in the develop-
ment of CNS agents acting on cholinergic neurotrans-
mission.This has been recently exemplified by studies
using REM sleep changes as surrogate markers of the
activity of acetylcholinesterase inhibitors.Drugs enhanc-
ing cholinergic transmission have been consistently
demonstrated to increase REM sleep pressure. In this
regard,cognitive enhancers involving a cholinergic mech-
anism have been shown to increase REM sleep amount,
to shorten REM latency,and to increase REM activity
and density.These characteristics are the sleep EEG “sig-
nature” of this class of drugs and could thus represent
surrogate markers of activity.
Aging, SWS, and 5-HT2 receptor antagonism
Role of SWS
It has long been assumed that sleep per se is essential for
the restoration of body and mind;research conducted over
the past three decades has led many experts to assume
that SWS is centrally involved in such restorative process.
In support of this assumption are numerous studies show-
ing that SWS is totally recovered following sleep depriva-
tion,
26 as well as several investigations linking SWS to
growth hormone (GH) secretion,
27,28 which contributes to
tissue repair.For instance,in monkeys,a positive correla-
tion between the duration of SWS and the level of cere-
bral protein synthesis has been demonstrated.
29
Investigations of sleep-related changes in heart rate and
blood pressure that found indices of parasympathetic
dominance during non-REM sleep and particularly SWS,
30
and positron emission tomography (PET) scan studies
showing that global cerebral glucose metabolism in
humans is lowest in SWS,
31 are findings that further sug-
gest a role of SWS in body restoration.
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Further evidence for a role of SWS in human somatic
restoration comes from studies showing that SWS
increases following daytime exercise
32-34 and from the
study of Kattler et al
35 showing that, in humans, slow
wave activity increases during SWS in the central area
contralateral to a prolonged vibratory hand stimulation
experienced during the previous waking period.
Regarding mental restorative processes,results of stud-
ies investigating the role of sleep in learning and mem-
ory suggest that memory formation is prompted by SWS-
related processes with REM sleep promoting memory
formation at a second stage (recently reviewed in refer-
ences 10 and 36).In this regard,some studies suggested
that cognitive performance (assessed through reaction
time tasks) is related to amounts of SWS in healthy
young volunteers
37 or to specific slow wave deficiencies
in older insomniacs.
38
Aging and SWS
Normal aging is characterized by the occurrence of several
sleep disturbances.
39 Polysomnographic recordings iden-
tify an increase in the number and duration of awakenings
during sleep and a lowering of SWS.
40,41 Nocturnal sleep is
found to be less restorative,and aged subjects are prone
to insomnia,daily somnolence,and napping.
42 Finally,since
many aspects of cognitive performance decline with aging,
it seems reasonable to question the relationship between
SWS and cognitive performance among older adults.
43 It
has been hypothesized that the amount of SWS could be
directly related to the efficiency of neuronal connections
in the cortex
44 and that aging leads to a decrease in the
physiological process (process S) inducing SWS and favor-
ing sleep continuity.
45,46
5-HT2 receptor and SWS
A body of evidence suggests that serotonergic transmis-
sion,particularly at the level of the 5-HT2A/C receptor,
plays a major role in the induction of process S and
SWS.
47 Drugs antagonizing the 5-HT2A/C receptor
increase SWS,whereas 5-HT2A/C agonists have the oppo-
site effect.
48 Spectral analysis of non-REM sleep shows a
huge increase in slow wave activity with compounds
blocking 5-HT2A/C transmission.
49,50Although some anti-
depressant and antipsychotic drugs display this 5-HT2A/C
antagonist profile and indeed have been shown to
increase SWS,
51,52 up to now there is no drug marketed for
sleep disorder that enhances SWS in a sustained manner.
In contrast,chronic benzodiazepine administration has
been shown to decrease SWS.
53 New nonbenzodiazepine
hypnotics acting at the GABAA receptor,such as zopi-
clone, zolpidem, and zaleplon, have a more favorable
profile in terms of sleep architecture,although none of
them has demonstrated sustained SWS enrichment after
repeated administration.
54
In this regard,5-HT2A/C receptor antagonists could thus
be of great interest for alleviating age-related sleep dis-
turbances and for ameliorating psychomotor and cogni-
tive functions by restoring deep SWS, particularly in
elderly insomniacs.There is preliminary evidence to sug-
gest that repeated administration of ritanserin 5 mg (a 
5-HT2A/C receptor antagonist) in middle-aged poor sleep-
ers decreases the frequencies of awakening and improves
subjective quality of sleep
55 and increases subjective alert-
ness in narcoleptic patients
56 and in young healthy vol-
unteers performing a driving test.
57 Furthermore, in
young healthy subjects, Gronfier et al
58 found that the
SWS enrichment induced by the acute administration of
ritanserin 5 mg is positively correlated to the amount of
GH secretion,suggesting a common 5-HT2a/c–triggered
stimulatory mechanism between GH secretion and delta
wave activity.
The question of whether antagonizing the 5-HT2A or 5-
HT2C receptor allows SWS enhancement is still unre-
solved.There are some data suggesting that 5-HT2C medi-
ates SWS,
59,60 but Landolt et al
49 showed substantial SWS
enhancement with SR 46349B,a specific 5-HT2A antago-
nist. Clozapine, which displays a weaker activity for 5-
HT2A receptors,does not seem to affect SWS in schizo-
phrenic patients or even tends to diminish it.Olanzapine
induces clear-cut SWS enhancement in healthy subjects
61,62;
these effects seem to be mediated by 5-HT2C receptors,
since allelic differences in the gene coding for this recep-
tor influence SWS responses to olanzapine.
63
In summary,compounds antagonizing 5-HT2A/C receptors
could be valuable drugs for age-related sleep disturbances.
In healthy subjects,studying drug-induced SWS alteration
is a particularly useful tool for the development of CNS-
acting compounds with 5-HT2A/C-blocking properties.
REM sleep alterations as surrogate markers of
antidepressant responsive conditions
Characteristic sleep EEG changes have been consis-
tently identified in depressive illness. Lengthening ofsleep latency,frequent nocturnal awakening,and early
morning wakening resulting in a decrease in total sleep
time are the hallmarks of sleep continuity disturbances
in major depression.With regard to sleep architecture,
a deficit of SWS,especially during the first sleep cycle,
has been consistently described.Disturbances in REM
sleep organization consist of an earlier onset of this
sleep stage, a greater amount of REM sleep at the
beginning of the night, and an increase in the actual
rapid eye movements (REM activity and REM den-
sity) during this sleep stage.
64,65There is some evidence
that these sleep abnormalities increase with the sever-
ity of the depression
66,67 and that they are more pro-
nounced in older patients.
41,68 Furthermore, some stud-
ies, which controlled for the effects of these variables,
indicate a comparable sleep EEG in different depres-
sive subtypes, including the bipolar/unipolar distinc-
tion,
69 but suggest a role for endogenous and psychotic
symptoms in the appearance of shortening of REM
latency.
70,71
Although the specificity of this sleep EEG profile to
depression is not fully established, it should be noted
that, according to Benca et al,
72 the most widespread
and the most severe disturbances are found in patients
with depressive disorder. Furthermore, REM sleep
alterations have been reported in antidepressant-
responsive conditions such as obsessive-compulsive 
disorder,
73 panic disorder,
74 depressed patients with
anorexia nervosa
75 or alcoholism,
76 and, by some
authors,in nondepressed patients with schizophrenia.
77
Thus, a body of evidence suggests that REM sleep dis-
turbances could relate to antidepressant-responsive psy-
chopathological states.It has been hypothesized that an
imbalance between aminergic and cholinergic influ-
ences underlie REM sleep disinhibition (earlier onset,
greater amount in the first part of the night,increase in
the number of  rapid eye movements) in depressive dis-
order.
78 Conversely, the ability of most antidepressant
drugs to inhibit REM sleep might be attributed to facil-
itation of noradrenergic and/or serotonergic function or
to muscarinic blockade.
52 In some cases,as with most tri-
cyclic antidepressants, all three mechanisms may be
involved.Antidepressant drugs without clear-cut REM
suppressant effects (ie, amineptine, bupropion, nefa-
zodone, tianeptine, trazodone, and trimipramine) have
a common characteristic: their potency for inhibiting
adrenergic or serotonergic uptake is either absent or
moderate.
79,80
Modeling a specific serotonergic and noradrenergic
depressive profile by acute monoamine depletion
Serotonergic and catecholaminergic neurotransmission
depletion paradigms have been shown to be useful
research tools to evaluate the role of these neurotrans-
mitter systems,both in the pathogenesis of depression and
in the mechanisms of antidepressant treatment modali-
ties.
81 It is postulated that sleep EEG disturbances in
response to serotonergic and catecholaminergic chal-
lenges reflect pathologically diminished levels of sero-
tonin or catecholamine release in depression,a condition
that could briefly be elicited in healthy subjects with these
depletion procedures.The only study to have tackled the
question lends support to the idea that the tryptophan
depletion test (TDT) in healthy subjects can mimic
depressed patients in terms of neuroendocrine response
to serotoninergic challenge; indeed, after performing a
TDT in healthy subjects,Coccaro et al
82 showed an attenu-
ated prolactin response to fenfluramine.Some studies
83-86
suggest that the TDT might be a valuable procedure to
elicit typical sleep abnormalities of depression, and, in
particular,an increased REM sleep pressure,a condition
assumed to be associated with response to antidepressant
drugs.It can be thus postulated that the TDT challenges
using REM sleep pressure as a surrogate marker of
depression might be useful models for studying the mech-
anisms of action of antidepressant drugs,since acute or
chronic antidepressant drug administration should inter-
fere with these sleep alterations.Indeed,in a recent study,
we were able to demonstrate that the effects of the sero-
tonin reuptake inhibitor fluvoxamine on REM sleep were
partially inhibited by TDT challenge.Further develop-
ments of this technique will include a study with a specific
noradrenergic reuptake inhibitor and  the phenylalanine
depletion challenge,and an attempt to replicate the sleep
animal data suggesting that specific monoamine depletion
could identify noradrenaline and serotonin reuptake
inhibitors.
87
Distinguishing the effects of SNRIs from those
of SSRIs on the basis of sleep EEG recordings
Selective serotonin reuptake inhibitors (SSRIs),selective
noradrenaline reuptake inhibitors (SNRIs), and dual
noradrenaline and serotonin reuptake inhibitors (NSRIs)
have all shown an REM-suppressant effect after single or
repeated administration to healthy volunteers (for recent
Clinical research
346Sleep-wake mechanisms and drug discovery - Staner Dialogues in Clinical Neuroscience - Vol 4 . No.4 . 2002
347
reviews of the effects of antidepressants on sleep see ref-
erences 52 and 88).There are also studies suggesting that
these three types of antidepressant exhibit alerting effects
(ie, tend to enhance vigilance and therefore induce
arousal during sleep),although data are more sparse for
SNRI and particularly NSRI. We suggest that sleep
microarchitecture could distinguish SSRI from SNRI.Up
to now,very few studies have investigated the effects of
antidepressant drugs on the EEG spectral power values.
For instance, the NSRI venlafaxine has been shown to
decrease the power of delta and theta waves and increase
fast beta-activities during non-REM sleep in depressed
patients, suggesting that this compound could lighten
sleep intensity.
89 Other studies
90,91 in depressed patients
showed that citalopram decreased the non-REM EEG
power in the 8 to 9 Hz range (lower alpha waves) and tra-
zodone decreased the non-REM EEG power in the 13 to
14 Hz range (lower beta waves). One study in healthy
subjects did not reveal any change in spectral power val-
ues in the delta,theta,alpha,beta,and gamma frequency
ranges after 4 weeks of paroxetine administration.
92There
are some indications in the literature suggesting that sero-
tonin and noradrenaline may play a different role in the
regulation of sleep;indeed noradrenaline could be impli-
cated in wake-promoting mechanisms and hyper-
arousal,
93,94 whereas serotonin could be more involved in
sleep-promoting mechanisms.
95,96 For instance, animal
studies suggest that noradrenaline and serotonin microin-
jections in the basal forebrain induce different modula-
tion of gamma EEG activity and of the sleep-wake state.
97
It can thus speculated that sleep microstructure,reflect-
ing these specific mechanisms, could be differently
affected by the single administration of an SSRI, an
SNRI,or an NSRI.
In summary, the sleep EEG profile of antidepressants
and particularly the effects on REM sleep are specific to
their ability to enhance noradrenergic or serotoninergic
transmission.It is suggested that the respective effects of
noradrenergic versus serotoninergic reuptake inhibition
could be disentangled using specific monoamine deple-
tion tests and by studying drug effects on sleep
microstructure.
Conclusions
Sleep EEG recordings constitute a unique noninvasive
tool to analyze brain functioning.The dynamic relation-
ships between brain neurotransmitter systems can be
directly addressed through the assessment of sleep phys-
iology. Neurotransmission disturbances, such as those
encountered in mental disorders,are reflected in spon-
taneous alteration of sleep continuity and architecture,or
in aberrant sleep EEG responses to the administration of
specific neuropsychopharmacological probes.Sleep lab-
oratory investigations are particularly well suited to eval-
uating objective effects of psychoactive drugs on sleep
and wakefulness.Moreover,new compounds can be com-
pared with reference drugs in terms of the sleep EEG
profile they induce.Finally,all-night sleep EEG spectral
analysis provides a matchless technique to study the way
drugs affect sleep microstructure,and therefore the core
of sleep regulation mechanisms. ❏
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Los mecanismos del sueño-vigilia y el 
descubrimiento de fármacos: el EEG de
sueño como una herramienta para el 
desarrollo de fármacos que actúan sobre 
el SNC
Las investigaciones de laboratorio de sueño consti-
tuyen una herramienta única, no invasora, para ana-
lizar el funcionamiento cerebral. Los registros poli-
somnográficos son mandatorios dentro del plan de
desarrollo de un nuevo compuesto que actúe sobre
el sueño,  aun en la fase muy precoz del desarrollo
en humanos. El sueño es también una herramienta
interesante para el desarrollo de otros fármacos que
actúen sobre el sistema nervioso central (SNC).
Verdaderamente, los cambios en las características
electroencefalográficas (EEG) del sueño representan
una indicación muy sensible de los efectos centrales
objetivos de fármacos psicoactivos. Estos cambios
son específicos en relación a la forma de actuación
del fármaco en los sistemas de neurotransmisión
central. Sin embargo, los nuevos fármacos se pue-
den comparar con fármacos de referencia en térmi-
nos del perfil EEG de sueño que ellos inducen. Por
ejemplo, se ha demostrado consistentemente que
los “aumentadores cognitivos” al incluir mecanis-
mos colinérgicos incrementan la carga de sueño con
movimientos oculares rápidos (MOR), y el estudio de
la alteración en el sueño de ondas lentas inducida
por fármacos es una herramienta particularmente
útil para el desarrollo de compuestos para el SNC
que actúan a nivel de receptores 5-HT2A/C como la
mayoría de los antipsicóticos atípicos y algunos fár-
macos antidepresivos. El perfil EEG de sueño de los
antidepresivos y, particularmente, los efectos sobre
el sueño MOR son específicos en su capacidad para
aumentar la transmisión noradrenérgica o seroto-
ninérgica. Se ha sugerido que los efectos particula-
res de la inhibición de la recaptación noradrenérgica
versus la inhibición de la recaptación serotoninér-
gica podrían ser aclarados utilizando pruebas espe-
cíficas de depleción de monoaminas y mediante el
estudio de los efectos de fármacos en la microes-
tructura del sueño.
Mécanismes de veille-sommeil et découverte
de médicaments : l’EEG de sommeil comme
outil pour le développement de molécules
agissant sur le SNC
L’exploration du sommeil en laboratoire constitue
un outil non invasif remarquable d’analyse du fonc-
tionnement cérébral. Les enregistrements poly-
somnographiques, même dans la phase très précoce
du développement chez l’homme, sont impératifs
dans le plan de développement d’une nouvelle
molécule agissant sur le sommeil. L’exploration du
sommeil est également un outil intéressant pour le
développement d’autres médicaments agissant sur
le système nerveux central (SNC). Les modifications
des caractéristiques de l’électroencéphalogramme
(EEG) au cours du sommeil sont en effet une indi-
cation très sensible des effets centraux objectifs des
molécules psychoactives, et ces modifications sont
spécifiques du mode d’action de la molécule sur les
neurotransmetteurs cérébraux. De plus, les nou-
veaux traitements peuvent être comparés aux
molécules de référence d’après le profil d’EEG de
sommeil qu’ils induisent. Ainsi, les molécules amé-
liorant la cognition par le biais du système choli-
nergique ont régulièrement démontré qu’elles aug-
mentaient la propension aux mouvements oculaires
rapides (MOR) durant le sommeil. L’étude des alté-
rations du sommeil à ondes lentes induites par les
médicaments est particulièrement utile pour le
développement de molécules du SNC agissant au
niveau du récepteur 5-HT2A/C, tels la plupart des
antipsychotiques atypiques et certains antidépres-
seurs. Le profil d’EEG de sommeil des antidépres-
seurs, et particulièrement les effets sur les MOR du
sommeil, sont spécifiques de leur capacité à aug-
menter la transmission noradrénergique ou séro-
toninergique. Il est suggéré que les effets respectifs
de l’inhibition de la recapture noradrénergique et
de l’inhibition de la recapture de la sérotonine
pourraient être démêlés grâce à des tests spéci-
fiques de déplétion des monoamines et en étudiant
les effets des traitements sur la microstructure du
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